Although several studies have highlighted the potential use of biomarkers as Galectin-3, Cystatin-C, and NGAL to identify DD in patients with different diseases, this represents the first study that assessed these and other relevant cardiovascular biomarkers in the context of CD and CCM (22, 25, 35). This evidence concerns the gene CST3 and cerebral cavernous malformation.